NSE: SUNPHARMA · BSE: 524715 · ISIN INE044A01036
Sun Pharmaceutical Industries Limited stock analysis
Sun Pharmaceutical Industries Limited ranks #886 in the TickerSutra evidence-ranked universe with a score of 59/100 and 95% data confidence. The latest captured fundamentals show ROCE of 20.5%, quarterly sales growth of 10.5% and quarterly profit growth of 6.0%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 20.5%
- Low debt/equity of 0.06×
- CWIP indicates an active capacity pipeline
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹38,654cr | ₹10,258cr | ₹3,389cr | 27.0% |
| 2023 | ₹43,886cr | ₹11,650cr | ₹8,513cr | 27.0% |
| 2024 | ₹48,497cr | ₹13,018cr | ₹9,610cr | 27.0% |
| 2025 | ₹52,578cr | ₹15,114cr | ₹10,965cr | 29.0% |
| 2026 | ₹58,462cr | ₹16,501cr | ₹11,509cr | 28.0% |
| TTM | ₹59,911cr | ₹17,847cr | ₹12,117cr | 30.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Completion and Result of Postal Ballot dated 25 August 2026'.
RoutineSun Pharmaceutical Industries Ltd - 524715 - Completion And Result Of Postal Ballot Dated 25 August 2026BSE · 29 Sept 2026Completion and Result of Postal Ballot dated 25 August 2026
RoutineSun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseBSE · 28 Sept 2026Press Release for lerodalcibep licensing agreement
RoutineGeneral UpdatesNSE · 27 Sept 2026Receipt of approval of the shareholders for reclassification of shareholder category
RoutineSun Pharmaceutical Industries Ltd - 524715 - Receipt Of Approval Of The Shareholders For Reclassification Of Shareholder CategoryBSE · 27 Sept 2026Receipt of approval of the shareholders for reclassification of shareholder category
MANAGEMENT COMMENTARY
Signals from filed documents
Gross sales increased by 11.9% to ₹ 582 Billion, while EBITDA rose by 16.1% to ₹ 177 Billion, reflecting operational strength and margin expansion. Growth was supported by a diversified business mix, with India contributing 34% of revenues and international markets accounting for 66%. The Company reported an adjusted net profit after minority interests of ₹ 124 Billion and increased its net worth to ₹ 836 Billion.
FY26 Highlights Sun Pharma delivered a strong performance in FY26, driven by growth across its India business, Global Innovative Medicines portfolio and international markets. Gross sales increased by 11.9% to ₹ 582 Billion, while EBITDA rose by 16.1% to ₹ 177 Billion, reflecting operational strength and margin expansion. Growth was supported by a diversified business mix, with India contributing 34% of revenues and
The country has strengthened its position in the global pharmaceutical industry through its manufacturing scale, scientific and commercial talent and ability to supply high-quality medicines competitively across markets. It is heartening to note that Indian pharmaceutical companies are participating more actively in complex generics, specialty products and innovation-led segments globally, further boosting local infr
Leadership across Key Pharmaceutical Markets We have established strong positions across our key markets through a broad product portfolio, deep customer relationships and consistent execution. Our market leadership reflects the trust placed in our products and capabilities by healthcare professionals, patients and partners worldwide. Largest Pharmaceutical company in India* 13th Largest generics company in the US ma
The business maintained its strong position in the market through a diversified portfolio spanning Innovative Medicines, Generics and OTC products, while continuing to rank among the leading generic pharmaceutical companies in the US. New Product Approvals and Launches and Acquisitions in the US Sun Pharma Signs Definitive Agreement to Acquire Organon Sun Pharma will acquire all outstanding shares of Organon for US$
FY26 was a year of steady progress for the Company as we continued to strengthen our business across markets while navigating a complex external environment. Regulatory shifts, pricing pressure, geopolitical uncertainty and evolving trade dynamics continued to influence the global pharmaceutical sector during the year. Our focus has remained on disciplined execution, improving portfolio quality and strengthening oper
During the year, we retained our position as #1 pharmaceutical company in India, with an 8.4% market share and leadership across 11 different doctor categories based on prescription volumes. Just like the past several years, I am pleased to note that our growth was led by an increase in volume and new product launches versus price increases. Our US business has continued to evolve significantly over time, with a high
41 Management Discussion and Analysis Advancing Innovation Globally for Better Patient Care Statutory Reports Corporate OverviewFinancial Statements Road Ahead • Sustained focus and investments in our focus brands with a view to driving category development • Leveraging our strong brand equity through the launch of relevant line extensions and building a portfolio of products across new formats and benefit segments •
Negative: Failure to comply with guidelines and regulations of clinical trials and animal testing can undermine the efficacy and safety of the Company’s clinical trials. It may also have an adverse regulatory/legal impact, lead to financial damages and reputation loss and have a negative impact on participant’s health and safety. Delays at any stage can also prolong the overall timeline for drug development, leading
This approach enables us to stay competitive across markets while expanding our innovation footprint. Our global manufacturing network comprises facilities approved by leading regulatory authorities, ensuring consistent quality and compliance across markets. We continue to strengthen operational efficiency, supply chain resilience and quality systems to support our expanding portfolio and global footprint.
Marg, Vikhroli West, Mumbai, India – 400083 T elephone: +91 810 811 6767 / (+91 22) 4918 6270 Email: investor.helpdesk@in.mpms.mugf.com Portal: https:/ /swayam.in.mpms.mufg.com/ Individual Investors Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 T elephone: (+91 22) 4324 4324 Email: secretarial@sunpharma.com Institutional Investors Dr. Abhishe
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…